$23.39
2.99% today
Nasdaq, Apr 04, 08:15 pm CET
ISIN
US14888U1016
Symbol
CPRX
Sector
Industry

Catalyst Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Catalyst Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
100%

Catalyst Pharmaceuticals, Inc. Price Target

Target Price $34.29
Price $24.11
Potential
Number of Estimates 7
7 Analysts have issued a price target Catalyst Pharmaceuticals, Inc. 2026 . The average Catalyst Pharmaceuticals, Inc. target price is $34.29. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 7 analysts: 7 Analysts recommend Catalyst Pharmaceuticals, Inc. to buy, 0 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Catalyst Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Catalyst Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 491.73 555.14
23.49% 12.90%
EBITDA Margin 47.42% 36.11%
57.41% 23.85%
Net Margin 32.20% 31.03%
68.39% 3.64%

7 Analysts have issued a sales forecast Catalyst Pharmaceuticals, Inc. 2025 . The average Catalyst Pharmaceuticals, Inc. sales estimate is

$555m
Unlock
. This is
12.90% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$559m 13.64%
Unlock
, the lowest is
$550m 11.92%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $492m 23.49%
2025
$555m 12.90%
Unlock
2026
$609m 9.61%
Unlock
2027
$686m 12.81%
Unlock
2028
$770m 12.20%
Unlock
2029
$851m 10.44%
Unlock

1 Analyst has issued an EBITDA forecast Catalyst Pharmaceuticals, Inc. 2025 . The average Catalyst Pharmaceuticals, Inc. EBITDA estimate is

$200m
Unlock
. This is
14.04% lower
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
$200m 14.04%
Unlock
, the lowest is
$200m 14.04%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $233m 94.38%
2025
$200m 14.04%
Unlock
2026
$271m 35.43%
Unlock

EBITDA Margin

2024 47.42% 57.41%
2025
36.11% 23.85%
Unlock
2026
44.61% 23.54%
Unlock

6 Catalyst Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Catalyst Pharmaceuticals, Inc. net profit estimate is

$172m
Unlock
. This is
8.78% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$213m 34.35%
Unlock
, the lowest is
$151m 4.58%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $158m 107.94%
2025
$172m 8.78%
Unlock
2026
$203m 17.67%
Unlock
2027
$225m 11.08%
Unlock
2028
$262m 16.33%
Unlock
2029
$295m 12.46%
Unlock

Net Margin

2024 32.20% 68.39%
2025
31.03% 3.64%
Unlock
2026
33.31% 7.35%
Unlock
2027
32.80% 1.53%
Unlock
2028
34.00% 3.66%
Unlock
2029
34.63% 1.85%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ 1.31 1.43
107.94% 9.16%
P/E 16.92
EV/Sales 4.35

6 Analysts have issued a Catalyst Pharmaceuticals, Inc. forecast for earnings per share. The average Catalyst Pharmaceuticals, Inc. EPS is

$1.43
Unlock
. This is
9.16% higher
Unlock
than earnings per share in the financial year 2024. The highest EPS forecast is
$1.76 34.35%
Unlock
, the lowest is
$1.25 4.58%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $1.31 107.94%
2025
$1.43 9.16%
Unlock
2026
$1.68 17.48%
Unlock
2027
$1.86 10.71%
Unlock
2028
$2.17 16.67%
Unlock
2029
$2.44 12.44%
Unlock

P/E ratio

Current 18.42 29.61%
2025
16.92 8.14%
Unlock
2026
14.38 15.01%
Unlock
2027
12.94 10.01%
Unlock
2028
11.13 13.99%
Unlock
2029
9.89 11.14%
Unlock

Based on analysts' sales estimates for 2025, the Catalyst Pharmaceuticals, Inc. stock is valued at an EV/Sales of

and an P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 4.91 12.10%
2025
4.35 11.44%
Unlock
2026
3.97 8.77%
Unlock
2027
3.52 11.36%
Unlock
2028
3.13 10.88%
Unlock
2029
2.84 9.45%
Unlock

P/S ratio

Current 5.95 26.21%
2025
5.27 11.42%
Unlock
2026
4.81 8.77%
Unlock
2027
4.27 11.35%
Unlock
2028
3.80 10.88%
Unlock
2029
3.44 9.45%
Unlock

Current Catalyst Pharmaceuticals, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Baird
Locked
Locked
Locked Mar 03 2025
HC Wainwright & Co.
Locked
Locked
Locked Feb 28 2025
Stephens & Co.
Locked
Locked
Locked Feb 27 2025
Baird
Locked
Locked
Locked Feb 04 2025
HC Wainwright & Co.
Locked
Locked
Locked Jan 10 2025
B of A Securities
Locked
Locked
Locked Jan 09 2025
Stephens & Co.
Locked
Locked
Locked Nov 18 2024
Analyst Rating Date
Locked
Baird:
Locked
Locked
Mar 03 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Feb 28 2025
Locked
Stephens & Co.:
Locked
Locked
Feb 27 2025
Locked
Baird:
Locked
Locked
Feb 04 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jan 10 2025
Locked
B of A Securities:
Locked
Locked
Jan 09 2025
Locked
Stephens & Co.:
Locked
Locked
Nov 18 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today